Guay D R, Meatherall R C, Chalmers J L, Grahame G R, Hudson R J
Br J Clin Pharmacol. 1985 Jul;20(1):55-9. doi: 10.1111/j.1365-2125.1985.tb02798.x.
The effect of concurrent ranitidine administration on the disposition of pethidine was investigated in eight healthy male volunteers (19-33 years). The subjects received 70 mg i.v. pethidine HCl doses before and during ranitidine treatment (150 mg p.o. twice daily). Ranitidine therapy was not associated with significant alterations in pethidine elimination rate constant, volume of distribution at steady state, total body clearance, and 24 h urinary excretion. No alteration in pethidine oxidation to norpethidine was noted, as suggested by nonsignificant changes in lag time to appearance of quantifiable norpethidine in serum, time to peak concentration, peak concentration, area under the curve from time 0.24 h, and 24 h urinary excretion. It would appear that, unlike cimetidine, ranitidine does not interact pharmacokinetically with pethidine. Further studies are necessary to evaluate the potential clinical advantages of ranitidine vs cimetidine therapy in patients also receiving pethidine.
在8名健康男性志愿者(19 - 33岁)中研究了同时给予雷尼替丁对哌替啶处置的影响。受试者在雷尼替丁治疗前(每日口服150mg,分两次)和治疗期间接受了70mg静脉注射盐酸哌替啶剂量。雷尼替丁治疗与哌替啶消除速率常数、稳态分布容积、全身清除率和24小时尿排泄量的显著改变无关。血清中可定量的去甲哌替啶出现的滞后时间、达峰时间、峰浓度、0至24小时曲线下面积以及24小时尿排泄量的变化均无统计学意义,这表明哌替啶氧化为去甲哌替啶没有改变。似乎与西咪替丁不同,雷尼替丁在药代动力学上不与哌替啶相互作用。有必要进行进一步研究以评估雷尼替丁与西咪替丁治疗对同时接受哌替啶治疗的患者的潜在临床优势。